Anti-C1GALT1 antibody produced in rabbit

C1GALT1 (core 1 synthase, glycoprotein-N-acetylgalactosamine 3-β-galactosyltransferase 1) is a mucin-type O-glycosyltransferase, which resides in Golgi bodies. It is a type II transmembrane protein with its N-terminal facing the cytosol. Its transmembrane domain is made of 26 amino acids, and its functional domain is made of 331 amino acids and faces the lumen.

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

C1GALT1 (core 1 synthase, glycoprotein-N-acetylgalactosamine 3-β-galactosyltransferase 1) catalyzes the transfer of galactose (Gal) to N-acetylgalactosamine (GalNAc) of a serine (Ser) or threonine (Thr) residue (Tn antigen) to form the Galβ1-3GalNAcα1-Ser/Thr structure. This structure is called the T antigen or core 1 structure, which acts as the precursor for maturation of mucin-type O-glycans. This protein is also involved in the control of kidney development, thrombopoiesis and angiogenesis. It is up-regulated in hepatocellular carcinoma (HCC) and is responsible for enhanced proliferation of HCC cells. This is achieved by the activation of hepatocyte growth factor (HGF) by C1GALT1, through modulation of MET O-glycosylation. It is responsible for the enhanced invasiveness of colon cancer via the modification of the O-glycosylation of FGFR2 (fibroblast growth factor receptor 2). Polymorphisms in C1GLAT1 gene are linked with Henoch-Schönlein purpura in Chinese population.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST71747

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.